RARITAN, N.J., Dec. 15 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of complicated intra-abdominal and complicated urinary tract infections. Doripenem has demonstrated activity against a wide range of Gram-positive and Gram-negative bacteria including Pseudomonas.
